The effect of amantadine on corneal endothelium in subjects with Parkinson's disease.
OBJECTIVE
To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.


METHODS
Cross-sectional study.


METHODS
A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.


METHODS
Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.


METHODS
Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.


RESULTS
The amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group.


CONCLUSIONS
Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.
Chang
Ki Cheol
KC
Department of Ophthalmology, Seoul National University College of Medicine, Chongno-gu, Seoul, Korea.
Jeong
Jin Ho
JH
Kim
Mee Kum
MK
Wee
Won Ryang
WR
Lee
Jin Hak
JH
Jeon
Beom Seok
BS
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002452:Cell Count; D003316:Corneal Diseases / Q000139:chemically induced* / Q000473:pathology; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D000547:Amantadine